BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1329621)

  • 1. Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci.
    Miranda AG; Wanger AR; Singh KV; Murray BE
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1325-8. PubMed ID: 1329621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.
    Korten V; Tomayko JF; Murray BE
    Antimicrob Agents Chemother; 1994 Mar; 38(3):611-5. PubMed ID: 8203863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
    Coque TM; Singh KV; Murray BE
    J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
    Rotstein C; Amsterdam D; Beam TR; Mandell LA; Gorzynski EA
    Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
    Jones RN; Beach ML; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):247-52. PubMed ID: 9884844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of new benzenesulphonamide fluoroquinolones structurally related to ciprofloxacin against selected ciprofloxacin-susceptible and -resistant Gram-positive cocci.
    Alovero F; Barnes A; Nieto M; Mazzieri MR; Manzo RH
    J Antimicrob Chemother; 2001 Nov; 48(5):709-12. PubMed ID: 11679560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of temafloxacin against gram-positive cocci including methicillin-resistant Staphylococcus aureus.
    Fuchs PC
    Am J Med; 1991 Dec; 91(6A):15S-18S. PubMed ID: 1662886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
    Wallrauch C; Voss A; Milatovic D; Braveny I
    Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
    Hardy D; Amsterdam D; Mandell LA; Rotstein C
    Antimicrob Agents Chemother; 2000 Mar; 44(3):802-5. PubMed ID: 10681365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of CP-74667 compared with four other fluoroquinolones.
    Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1992 Aug; 15(6):531-6. PubMed ID: 1330419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
    Endtz HP; Mouton JW; den Hollander JG; van den Braak N; Verbrugh HA
    Antimicrob Agents Chemother; 1997 May; 41(5):1146-9. PubMed ID: 9145886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro comparison of E4868, a new trifluoroquinolone, with ciprofloxacin and temafloxacin tested against 5192 recent clinical isolates from five medical centers.
    Murray PR; Jones RN; Washington JA; Gerlach EH; Allen SD
    Diagn Microbiol Infect Dis; 1993; 17(4):307-11. PubMed ID: 8112046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.
    Jones RN; Pfaller MA; Stilwell M;
    Diagn Microbiol Infect Dis; 2001 Feb; 39(2):133-5. PubMed ID: 11248528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of T-3761, a new fluoroquinolone.
    Muratani T; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates.
    López-Brea M; Prieto N; Domingo D; de las Cuevas C; Sánchez I; Alarcón T
    Int J Antimicrob Agents; 1999 Jun; 12(1):33-9. PubMed ID: 10389645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of new quinolones against ciprofloxacin-resistant staphylococci.
    Forstall GJ; Knapp CC; Washington JA
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1679-81. PubMed ID: 1656873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of temafloxacin for gram-positive pathogens.
    Bille J; Glauser MP
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():9-14. PubMed ID: 1664835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.